Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621010 · ClinicalTrials.gov registry record · Phase 1
Safety Study of CTS21166 to Treat Alzheimer Disease
A Phase 1 study of Alzheimers Disease, sponsored by CoMentis.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00621010: Completed Phase 1 study of Alzheimers Disease, sponsored by CoMentis.
NCT00621010 is a Phase 1 study of Alzheimers Disease that has completed, run by CoMentis. The registered enrollment target is 56 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621010, a Phase 1 study of Alzheimers Disease, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
Conditions Studied
Interventions
- DRUG CTS21166 (ZPQ-21166)
Study Locations (1)
Utah
- Lifetree Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621010
The ClinicalTrials.gov registry entry for NCT00621010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is CoMentis, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which CTS21166 (ZPQ-21166) is the first listed.
NCT00621010 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT00621010 about?
NCT00621010 is a clinical study titled "Safety Study of CTS21166 to Treat Alzheimer Disease". This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
What is the current status of trial NCT00621010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-06. Estimated completion is 2008-02.
What conditions does trial NCT00621010 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00621010?
The interventions under investigation include: CTS21166 (ZPQ-21166) (DRUG).
Who is sponsoring clinical trial NCT00621010?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621010 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.